# Naltrexone

## Naltrexone 50mg (專案進口)

##### 

| TAH Drug Code      | ONAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Alcohol use disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | (Micromedex) Alcohol dependence, Maintenance of abstinence: 50 mg orally once daily for <= 12 weeks. Opioid dependence: 25 mg orally on day 1; if no withdrawal signs occur, may increase to 50 mg orally once daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to naltrexone or any component of the formulation; current physiological opioid dependence or current use of opioid analgesics (including partial opioid agonists); acute opioid withdrawal; failure to pass naloxone challenge or positive urine screen for opioids                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | >10%: Syncope (=<13%), Headache (25%), insomnia (=<14%), sleep disorder (=<14%), dizziness (=<13%), anxiety (12%), Nausea (33%), vomiting (14%), anorexia (=<14%), change in appetite (=<14%), decreased appetite (=<14%), diarrhea (13%), abdominal pain (11%), Increased serum transaminases (20%), increased serum aspartate aminotransferase (2% to 14%), Increased creatine phosphokinase in blood specimen (11% to 39%), asthenia (23%), arthralgia (=<12%), arthritis (=<12%), joint stiffness (=<12%), Pharyngitis (11%) 1% to 10%: Depression (8% to 10%), drowsiness (=<4%), sedated state (=<4%), suicidal ideation (=<1%), suicidal tendencies (=<1%), Skin rash (6%), Xerostomia (5%), Muscle cramps (8%), back pain (=<6%), back stiffness (=<6%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

